Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 2.3.1.5 - arylamine N-acetyltransferase and Organism(s) Homo sapiens and UniProt Accession P11245

for references in articles please use BRENDA:EC2.3.1.5
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
Wide specificity for aromatic amines, including serotonin; also catalyses acetyl-transfer between arylamines without CoA.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
UNIPROT: P11245
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
hide
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Synonyms
serotonin n-acetyltransferase, arylamine n-acetyltransferase, arylamine n-acetyltransferase 1, arylamine n-acetyltransferase 2, tbnat, arylamine acetyltransferase, n-acetyltransferase a, nat 1, acetyl-coa:arylamine n-acetyltransferase, n-acetyltransferase type 2, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
arylamine N-acetyltransferase
-
arylamine N-acetyltransferase 1
-
arylamine N-acetyltransferase 2
-
arylamine N-acetyltransferase type 2
-
2-naphthylamine N-acetyltransferase
-
-
-
-
4-aminobiphenyl N-acetyltransferase
-
-
-
-
acetyl CoA-arylamine N-acetyltransferase
-
-
-
-
acetyltransferase, 2-naphthylamine N-
-
-
-
-
acetyltransferase, 4-aminobiphenyl
-
-
-
-
acetyltransferase, arylamine
-
-
-
-
acetyltransferase, p-aminosalicylate N-
-
-
-
-
acetyltransferase, procainamide N-
-
-
-
-
acetyltransferase, serotonin N-
-
-
-
-
arylamine acetylase
-
-
-
-
arylamine acetyltransferase
-
-
-
-
arylamine N-acetyltransferase
-
-
arylamine N-acetyltransferase 2
-
-
arylamine N-acetyltransferase I
-
-
arylamine N-acetyltransferase type 1
-
-
arylamine N-acetyltransferase type I
-
arylamine-N-acetyltransferase 1
-
-
beta-naphthylamine N-acetyltransferase
-
-
-
-
indoleamine N-acetyltransferase
-
-
-
-
N-acetyltransferase
-
-
-
-
NAT 1
-
-
p-aminosalicylate N-acetyltransferase
-
-
-
-
serotonin acetyltransferase
-
-
-
-
serotonin N-acetyltransferase
-
-
-
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
acetyl-CoA + an arylamine = CoA + an N-acetylarylamine
show the reaction diagram
acetyl-CoA + an arylamine = CoA + an N-acetylarylamine
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Acyl group transfer
-
Acyl group transfer
SYSTEMATIC NAME
IUBMB Comments
acetyl-CoA:arylamine N-acetyltransferase
Wide specificity for aromatic amines, including serotonin; also catalyses acetyl-transfer between arylamines without CoA.
CAS REGISTRY NUMBER
COMMENTARY hide
9027-33-2
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
4-nitrophenyl acetate + 4-amino-3-methylbenzoic acid
4-nitrophenol + N-acetyl-4-amino-3-methylbenzoic acid
show the reaction diagram
4-nitrophenyl acetate + 4-aminobenzoic acid
4-nitrophenol + N-acetyl-4-aminobenzoic acid
show the reaction diagram
4-nitrophenyl acetate + 4-aminobiphenyl
4-nitrophenol + N-acetyl-4-aminobiphenyl
show the reaction diagram
4-nitrophenyl acetate + 5-aminosalicylic acid
4-nitrophenol + 5-acetylaminosalicylic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + 2-aminofluorene
CoA + 2-acetylaminofluorene
show the reaction diagram
acetyl-CoA + 2-aminofluorene
CoA + N-acetyl-2-aminofluorene
show the reaction diagram
acetyl-CoA + 2-toluidine
CoA + N-acetyl-2-toluidine
show the reaction diagram
-
-
-
?
acetyl-CoA + 4,4'-methylenebis(2-chloroaniline)
CoA + N-acetyl-4,4'-methylenebis(2-chloroaniline)
show the reaction diagram
-
-
-
?
acetyl-CoA + 4-aminobenzoate
CoA + N-acetyl-4-aminobenzoate
show the reaction diagram
acetyl-CoA + 4-aminosalicylic acid
CoA + N-acetyl-4-aminosalicylic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + 4-aminoveratrole
CoA + N-acetyl-4-aminoveratrole
show the reaction diagram
57% activity compared to hydralazine
-
-
?
acetyl-CoA + 4-bromoaniline
CoA + N-acetyl-4-bromoaniline
show the reaction diagram
72% activity compared to hydralazine
-
-
?
acetyl-CoA + 4-chloroaniline
CoA + N-acetyl-4-chloroaniline
show the reaction diagram
71% activity compared to hydralazine
-
-
?
acetyl-CoA + 4-dimethylaminobenzaldehyde
CoA + 5-acetyl-4-dimethylaminobenzaldehyde
show the reaction diagram
-
-
-
?
acetyl-CoA + 4-hexyloxyaniline
CoA + N-acetyl-4-hexyloxyaniline
show the reaction diagram
51% activity compared to hydralazine
-
-
?
acetyl-CoA + 4-iodoaniline
CoA + N-acetyl-4-iodoaniline
show the reaction diagram
65% activity compared to hydralazine
-
-
?
acetyl-CoA + 4-methoxyaniline
CoA + N-acetyl-4-methoxyaniline
show the reaction diagram
9% activity compared to hydralazine
-
-
?
acetyl-CoA + 4-phenoxyaniline
CoA + N-acetyl-4-phenoxyaniline
show the reaction diagram
62% activity compared to hydralazine
-
-
?
acetyl-CoA + 5-aminosalicylate
CoA + N-acetyl-5-aminosalicylate
show the reaction diagram
64% activity compared to hydralazine
-
-
?
acetyl-CoA + 5-aminosalicylic acid
CoA + 5-acetylaminosalicylic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + 5-aminosalicylic acid
CoA + N-acetyl-5-aminosalicylic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + an arylamine
CoA + an N-acetylarylamine
show the reaction diagram
acetyl-CoA + hydralazine
CoA + N-acetylhydralazine
show the reaction diagram
100% activity
-
-
?
acetyl-CoA + isoniazid
?
show the reaction diagram
inactivation of the anti-tubercular drug isoniazid by acetyltransfer
-
-
?
acetyl-CoA + isoniazid
CoA + N-acetyl-isoniazid
show the reaction diagram
-
-
-
?
acetyl-CoA + isoniazid
CoA + N-acetylisoniazid
show the reaction diagram
acetyl-CoA + N-(4-aminobenzoyl)-L-glutamate
CoA + CoA + N-(4-acetylaminobenzoyl)-L-glutamate
show the reaction diagram
-
-
-
?
acetyl-CoA + N-(4-aminobenzoyl)-L-glutamate
CoA + N-(4-acetylaminobenzoyl)-L-glutamate
show the reaction diagram
3% activity compared to hydralazine
-
-
?
acetyl-CoA + p-aminobenzoic acid
CoA + N-acetyl-p-aminobenzoic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + procainamide
CoA + N-acetyl-2-procainamide
show the reaction diagram
-
-
-
?
acetyl-CoA + sulfamethazine
?
show the reaction diagram
-
-
-
?
acetyl-CoA + sulfamethazine
CoA + N-acetyl-sulfamethazine
show the reaction diagram
acetyl-CoA + sulfamethazine
CoA + N-acetylsulfamethazine
show the reaction diagram
46% activity compared to hydralazine
-
-
?
3'-dephospho-acetyl-CoA + 4-aminobenzoate
3'-dephospho-CoA + N-acetyl-4-aminobenzoate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl acetate + 3,4-dichloroaniline
4-nitrophenol + N-acetyl-3,4-dichloroaniline
show the reaction diagram
-
-
-
?
4-nitrophenyl acetate + 4-amino-3-methylbenzoic acid
4-nitrophenol + N-acetyl-4-amino-3-methylbenzoic acid
show the reaction diagram
4-nitrophenyl acetate + 4-aminobenzoate
4-nitrophenol + N-acetyl-4-aminobenzoate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl acetate + 4-aminobenzoic acid
4-nitrophenol + N-acetyl-4-aminobenzoate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl acetate + 4-aminobenzoic acid
4-nitrophenol + N-acetyl-4-aminobenzoic acid
show the reaction diagram
4-nitrophenyl acetate + 4-aminobiphenyl
4-nitrophenol + N-acetyl-4-aminobiphenyl
show the reaction diagram
4-nitrophenyl acetate + 5-aminosalicylic acid
4-nitrophenol + 5-acetylaminosalicylic acid
show the reaction diagram
-
-
-
?
a protein + 1-[4-[(6-azidohexyl)oxy]phenyl]-1-hydroxypropan-2-one
?
show the reaction diagram
-
-
-
?
a protein + 5-azido-N-[[4-(1-hydroxy-2-oxopropyl)phenyl]methyl]pentanamide
?
show the reaction diagram
-
-
-
?
a protein + N-(5-azidopentyl)-4-(1-hydroxy-2-oxopropyl)benzamide
?
show the reaction diagram
-
-
-
?
acetyl-CoA + (1-methyl-5-piperazin-1-yl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-(5-methyl-pyridin-2-yl)-amine
CoA + ?
show the reaction diagram
-
i.e. UK-469,413. Acetylation by isozyme NAT2 in liver cytosol to N-acetylpiperazine metabolite
-
-
?
acetyl-CoA + 2,3-dimethylaniline
CoA + N-acetyl-2,3-dimethylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 2,4-dimethylaniline
CoA + N-acetyl-2,4-dimethylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 2,5-dimethylaniline
CoA + N-acetyl-2,5-dimethylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 2-(4-aminobenzamido)pyridine
CoA + 2-(4-acetylamidobenzamido)pyridine
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 2-aminobenzoic acid
CoA + N-acetyl-2-aminobenzoic acid
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 2-aminofluorene
CoA + 2-acetylaminofluorene
show the reaction diagram
acetyl-CoA + 2-aminofluorene
CoA + N-acetyl-2-aminofluorene
show the reaction diagram
acetyl-CoA + 2-ethylaniline
CoA + N-acetyl-2-ethylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 2-methylaniline
CoA + N-acetyl-2-methylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 2-toluidine
CoA + N-acetyl-2-toluidine
show the reaction diagram
-
-
-
?
acetyl-CoA + 3,4-dimethylaniline
CoA + N-acetyl-3,4-dimethylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 3,5-dimethylaniline
CoA + N-acetyl-3,5-dimethylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 3-ethylaniline
CoA + N-acetyl-3-ethylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 4-aminobenzoate
CoA + N-acetyl-4-aminobenzoate
show the reaction diagram
acetyl-CoA + 4-aminobenzoic acid
CoA + 4-(acetylamino)benzoic acid
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 4-aminobenzoic acid
CoA + 4-acetylaminobenzoic acid
show the reaction diagram
acetyl-CoA + 4-aminobenzoic acid
CoA + N-acetyl-4-aminobenzoic acid
show the reaction diagram
acetyl-CoA + 4-aminobiphenyl
CoA + N-acetyl-4-aminobiphenyl
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 4-aminosalicylate
CoA + N-acetyl-4-aminosalicylate
show the reaction diagram
-
substrate for isoform NAT1
-
-
?
acetyl-CoA + 4-aminosalicylic acid
CoA + 4-acetylamino-2-hydroxybenzoate
show the reaction diagram
acetyl-CoA + 4-aminosalicylic acid
CoA + N-acetyl-4-aminosalicylic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + 4-dimethylaminobenzaldehyde
CoA + 5-acetyl-4-dimethylaminobenzaldehyde
show the reaction diagram
-
-
-
?
acetyl-CoA + 4-ethylaniline
CoA + N-acetyl-4-ethylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 4-methylaniline
CoA + N-acetyl-4-methylaniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 5-aminosalicylic acid
CoA + 5-acetylamino-2-hydroxybenzoate
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 5-aminosalicylic acid
CoA + 5-acetylaminosalicylic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + 5-aminosalicylic acid
CoA + N-acetyl-5-aminosalicylic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + 8-aminoisoindolo (1,2-b)quinazolin-12(10H)-one
?
show the reaction diagram
-
batricylin, an antitumor agent, is shown to be a substrate for NAT2
-
-
?
acetyl-CoA + an arylamine
CoA + a N-acetylarylamine
show the reaction diagram
acetyl-CoA + an arylamine
CoA + an N-acetylarylamine
show the reaction diagram
acetyl-CoA + aniline
CoA + N-acetyl-aniline
show the reaction diagram
-
-
-
-
?
acetyl-CoA + diaminodiphenylsulfone
monoacetyldiaminodiphenylsulfone + CoA
show the reaction diagram
-
i.e. dapsone, predominantly acetylated by NAT2
-
-
?
acetyl-CoA + hydralazine
CoA + N-acetylhydralazine
show the reaction diagram
-
substrate for isoform NAT2
-
-
?
acetyl-CoA + isoniazid
?
show the reaction diagram
-
-
-
-
?
acetyl-CoA + isoniazid
CoA + N-acetyl-isoniazid
show the reaction diagram
-
-
-
-
?
acetyl-CoA + isoniazid
CoA + N-acetylisoniazid
show the reaction diagram
-
-
-
?
acetyl-CoA + isoniazide
CoA + acetylniazide
show the reaction diagram
-
-
-
-
?
acetyl-CoA + N-(4-aminobenzoyl)-L-glutamate
CoA + N-(4-acetylaminobenzoyl)-L-glutamate
show the reaction diagram
acetyl-CoA + p-aminobenzoic acid
CoA + N-acetyl-4-aminobenzoic acid
show the reaction diagram
acetyl-CoA + p-aminobenzoic acid
CoA + N-acetyl-aminobenzoic acid
show the reaction diagram
-
-
-
-
?
acetyl-CoA + p-aminobenzoic acid
CoA + N-acetyl-p-aminobenzoic acid
show the reaction diagram
-
-
-
?
acetyl-CoA + p-aminobenzoylglutamate
CoA + N-[(4-acetylamino)]benzoyl-L-glutamate
show the reaction diagram
-
-
-
-
?
acetyl-CoA + p-aminosalicylic acid
CoA + N-acetyl-4-aminosalicylic acid
show the reaction diagram
-
-
-
-
?
acetyl-CoA + peptide
CoA + Nalpha-acetylpeptide
show the reaction diagram
-
-
-
-
?
acetyl-CoA + procainamide
CoA + N-acetyl-2-procainamide
show the reaction diagram
-
-
-
?
acetyl-CoA + procainamide
CoA + N-acetylprocainamide
show the reaction diagram
acetyl-CoA + sulfadiazine
CoA + ?
show the reaction diagram
-
-
-
-
?
acetyl-CoA + sulfadiazine
CoA + N-acetylsulfadiazine
show the reaction diagram
-
-
-
-
?
acetyl-CoA + sulfamerazine
CoA + ?
show the reaction diagram
-
-
-
-
?
acetyl-CoA + sulfamethazine
?
show the reaction diagram
-
-
-
?
acetyl-CoA + sulfamethazine
CoA + N-4-acetylsulfamethazine
show the reaction diagram
acetyl-CoA + sulfamethazine
CoA + N-acetyl-sulfamethazine
show the reaction diagram
p-nitrophenylacetate + p-aminosalicylic acid
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
4-nitrophenyl acetate + 4-amino-3-methylbenzoic acid
4-nitrophenol + N-acetyl-4-amino-3-methylbenzoic acid
show the reaction diagram
-
-
-
?
4-nitrophenyl acetate + 4-aminobenzoic acid
4-nitrophenol + N-acetyl-4-aminobenzoic acid
show the reaction diagram
a sunscreen additive
-
-
?
4-nitrophenyl acetate + 4-aminobiphenyl
4-nitrophenol + N-acetyl-4-aminobiphenyl
show the reaction diagram
a tobacco smoke carcinogen
-
-
?
acetyl-CoA + 2-aminofluorene
CoA + 2-acetylaminofluorene
show the reaction diagram
-
-
-
?
acetyl-CoA + an arylamine
CoA + an N-acetylarylamine
show the reaction diagram
4-nitrophenyl acetate + 4-amino-3-methylbenzoic acid
4-nitrophenol + N-acetyl-4-amino-3-methylbenzoic acid
show the reaction diagram
-
-
-
?
4-nitrophenyl acetate + 4-aminobenzoic acid
4-nitrophenol + N-acetyl-4-aminobenzoic acid
show the reaction diagram
a sunscreen additive
-
-
?
4-nitrophenyl acetate + 4-aminobiphenyl
4-nitrophenol + N-acetyl-4-aminobiphenyl
show the reaction diagram
a tobacco smoke carcinogen
-
-
?
acetyl-CoA + 2-aminofluorene
CoA + 2-acetylaminofluorene
show the reaction diagram
-
-
-
-
?
acetyl-CoA + an arylamine
CoA + a N-acetylarylamine
show the reaction diagram
acetyl-CoA + an arylamine
CoA + an N-acetylarylamine
show the reaction diagram
acetyl-CoA + peptide
CoA + Nalpha-acetylpeptide
show the reaction diagram
-
-
-
-
?
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
acetyl-CoA
acetyl-CoA
folate
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
alpha-solanine
noncompetitive, alpha-solanine can significantly decrease NAT activity in intact Hep-G2 cells or the cytoplasm. Km does not differ either for intact HepG2 cells or for the cytoplasm, while Vmax is significantly different
curcumin
non-competitive
kaemferol
non-competitive
quercetin
non-competitive
(-)-epigallocatechin-3-O-gallate
EGCG, non-competitive
(5E)-5-[(4-hydroxy-3,5-diiodophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
25fold more selective towards the inhibition of recombinant human NAT1 than N-acetyltransferase 2. Incubation of MDA-MB-231 cell line with (5E)-5-[(4-hydroxy-3,5-diiodophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one results in 60% reduction in NAT1 activity and significant decreases in cell growth, anchorage-dependent growth, and anchorage-independent growth
(5Z)-3-amino-5-(3-hydroxy-2,4-diiodobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
inhibition of both recombinant enzyme and native enzyme in ZR-75 cell lysate, competitive
(5Z)-5-(2-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
(5Z)-5-(2-methylbenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
inhibition of both recombinant enzyme and native enzyme in ZR-75 cell lysate, competitive
(5Z)-5-(3,4-dichlorobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
inhibition of both recombinant enzyme and native enzyme in ZR-75 cell lysate, competitive
(5Z)-5-(3-hydroxy-2,4-diiodobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
inhibition of both recombinant enzyme and native enzyme in ZR-75 cell lysate, competitive
(5Z)-5-(3-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
inhibition of both recombinant enzyme and native enzyme in ZR-75 cell lysate, competitive
(5Z)-5-(4-chlorobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
inhibition of both recombinant enzyme and native enzyme in ZR-75 cell lysate, competitive
1-butoxy-2-methylbenzene
-
-
2-bromoacetanilide
-
irreversible inhibitor
2-butoxyphenol
-
-
2-nitrosofluorene
2-nitrosotoluene
4-nitrosobenzene
-
less potent inactivator of NAT1, NAT1 with nitrosobenzene causes 59% inhibition of the enzyme, whereas the presence of AcCoA lowers the extent of inhibition to 13%
4-nitrosobiphenyl
5-methoxypsoralen
-
i.e. 5-MOP, activates the enzyme at 50 mM in Colo 205 cells, inhibitory at lower dosage of 0.05-0.5 mM, concentrations of 5-25 mM have no effect in Colo 205 cells
acetoaminophen
-
-
ATP
non-competitive inhibitor with respect to the acetyl acceptor, competitive inhibitor with respect to acetyl-coenzyme A. There is no effect by presence or absence of Mg2+
Benzyl isothiocyanate
-
-
beta-methylesculetin
-
inhibits NAT2 but not NAT1
caffeic acid
cisplatin
curcumin
-
inhibits NAT2 but not NAT1
cytokine
-
mixture of proinflammatory cytokines, interferon-gamma, interleukin-1beta, tumor necrosis factor-alpha
-
dihydrofolic acid
-
-
ellagic acid
-
-
ferulic acid
folic acid
-
competitive
gallic acid
glycyrrhizic acid
-
-
H2O2
-
NAT1 is reversibly inactivated by physiological aoncentrations of hydrogen peroxide. Inactivation of NAT1 is fully reversed by physiological concentrations of GSH
hydrogen peroxide
Ibuprofen
-
-
kaemferol
non-competitive
kaempferol
-
inhibits NAT1 and NAT2
Ketoprofen
-
competitive inhibitor of NAT enzymes
luteolin
-
-
methotrexate
-
competitive
N-(3-((2''-methoxyethyl)amino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(2''-chlorophenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3'',5''-dimethylphenoxy)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3'',5''-dimethylphenylamino)-5-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3'',5''-dimethylphenylamino)-6-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3'',5''-dimethylphenylamino)-7-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3'',5''-dimethylphenylamino)-8-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3''-chlorophenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3''-formylphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzamide
-
-
-
N-(3-(3''-formylphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(3''-formylphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)phenylacetamide
-
-
-
N-(3-(4''-bromophenoxy)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(4''-bromophenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(4''-chlorophenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(4''-formylphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(cyclopentylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(3-(furan-2''-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-benzenesulfonamide
-
-
-
N-(3-(furan-3''-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-benzenesulfonamide
-
-
-
N-(3-(furan-3''-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)phenylacetamide
-
-
-
N-(3-phenoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-benzenesulfonamide
-
-
-
N-(3-phenylamino-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-benzenesulfonamide
-
-
-
N-(5-amino-3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(6-amino-3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(7-amino-3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(8-amino-1,4-dioxo-3-(phenylamino)-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(8-amino-3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-(8-nitro-1,4-dioxo-3-(phenylamino)-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
-
-
-
N-ethylmaleimide
-
-
N-Hydroxy-2-acetylaminofluorene
-
mechanism-based inactivator, kinetics
N-[3-(3,5-dimethylanilino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl]-N-methylbenzenesulfonamide
-
-
N-[3-(3,5-dimethylanilino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl]benzenesulfonamide
nitrosobenzene
-
-
paclitaxel
-
inhibits NAT1 and NAT2
peroxinitrite
-
rapid and irreversible inactivation
peroxynitrite
phenethyl isothiocyanate
-
-
piperidinol
-
strong inhibition
proinflammatory cytokine
-
treatment of cholangiocarcinoma KKU-100 cells with cytokines (interferon-gamma, interleukin-1beta and tumor necrosis factor-alpha) suppresses NAT1 activity, reducing the Vmax without affecting the Km
-
quercetin
rhodanine
-
-
S-nitroso-glutathione
-
treatment of cholangiocarcinoma KKU-100 cells S-nitroso-glutathione results in reduced NAT1 activity as early as 2 h, and the suppression persists for 48 h
S-nitroso-N-acetyl-DL-penicillamine
-
reversible inactivation due to direct atteck of the highly reactive cysteine residue in the enzyme active site on the sulfur of S-nitrosothiols to form a mixed disulfide between these NO-derived oxidants and NAT1
S-nitrosoglutathione
-
-
SiO2
-
-
tamoxifen
-
-
thiram
irreversible inhibitor, modification of NAT1 catalytic cysteine residue
TiO2
-
-
vitamin C
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
5-methoxypsoralen
-
i.e. 5-MOP, activates the enzyme at 50 mM in Colo 205 cells, inhibitory at lower dosage of 0.05-0.5 mM in Colo 205 cells and at 0.5-0.25 mM in SC-M1 cells, concentrations of 5-25 mM have no effect in Colo 205 cells
glycyrrhizic acid
slightly activates isozyme NAT1
R1881
the androgen R1881 induces NAT1 activity in androgen receptor-positive prostate cancer cells
thermo-responsive diblock copolymer nanoparticle
-
-
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00222 - 0.00948
2-Aminofluorene
6.6
2-toluidine
pH 7.0, 23°C, isozyme NAT2, with 4-nitrophenyl acetate
0.048
4,4'-methylenebis(2-chloroaniline)
variant NAT2 4, pH 7.4, temperature not specified in the publication
11
4-amino-3-methylbenzoic acid
pH 7.0, 23°C, isozyme NAT2, with 4-nitrophenyl acetate
166
4-Aminobenzoic acid
pH 7.0, 23°C, isozyme NAT2, with 4-nitrophenyl acetate
0.184
5-aminosalicylic acid
isoform NAT 2, pH 7.4, 37°C
1.11 - 5.53
2,3-dimethylaniline
2.06 - 5.03
2,4-dimethylaniline
3.12 - 6.73
2,5-dimethylaniline
0.109 - 0.857
2-Aminofluorene
2.11
2-ethylaniline
-
-
2.32 - 7.18
2-methylaniline
1.2
2-toluidine
pH 7.0, 23°C, isozyme NAT1, with 4-nitrophenyl acetate
0.352 - 0.688
3,4-dimethylaniline
0.28 - 0.742
3,5-dimethylaniline
0.576 - 1.32
3-ethylaniline
0.17
4-amino-3-methylbenzoic acid
pH 7.0, 23°C, isozyme NAT1, with 4-nitrophenyl acetate
0.052 - 0.106
4-Aminobenzoate
0.049
4-Aminobenzoic acid
pH 7.0, 23°C, isozyme NAT1, with 4-nitrophenyl acetate
0.191 - 0.486
4-aminobiphenyl
0.205 - 3.27
4-ethylaniline
0.483 - 118
4-methylaniline
0.0067
5-aminosalicylic acid
isoform NAT 1, pH 7.4, 37°C
0.0543 - 0.651
acetyl-CoA
2.49 - 112
aniline
0.366 - 0.374
isoniazid
0.38 - 0.58
isoniazide
-
-
0.0028 - 152
p-Aminobenzoic acid
0.059 - 5.39
p-Aminosalicylic acid
45
procainamide
-
isozyme NAT1
3.1
Sulfadiazine
-
-
0.02 - 5.39
sulfamethazine
additional information
additional information
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
72
2-toluidine
pH 7.0, 23°C, isozyme NAT2, with 4-nitrophenyl acetate
16.6
4-amino-3-methylbenzoic acid
pH 7.0, 23°C, isozyme NAT2, with 4-nitrophenyl acetate
21
4-Aminobenzoic acid
pH 7.0, 23°C, isozyme NAT2, with 4-nitrophenyl acetate
27 - 256
2,3-dimethylaniline
67 - 661
2,4-dimethylaniline
5.7 - 313
2,5-dimethylaniline
449 - 759
2-Aminofluorene
61
2-ethylaniline
-
-
12 - 111
2-methylaniline
6.3
2-toluidine
pH 7.0, 23°C, isozyme NAT1, with 4-nitrophenyl acetate
461 - 800
3,4-dimethylaniline
308 - 1220
3,5-dimethylaniline
310 - 1960
3-ethylaniline
1.3
4-amino-3-methylbenzoic acid
pH 7.0, 23°C, isozyme NAT1, with 4-nitrophenyl acetate
127
4-Aminobenzoic acid
pH 7.0, 23°C, isozyme NAT1, with 4-nitrophenyl acetate
243 - 256
4-aminobiphenyl
430 - 700
4-ethylaniline
303 - 1600
4-methylaniline
281 - 711
aniline
38 - 298
p-Aminobenzoic acid
27 - 591
p-Aminosalicylic acid
387
sulfamethazine
-
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.01
quercetin
isozyme NAT2
0.54
4-nitrosobenzene
-
-
0.00067
4-nitrosobiphenyl
0.54
nitrosobenzene
-
recombinant NAT1
0.0486
quercetin
isozyme NAT1
0.023
thiram
37°C, pH not specified in the publication
additional information
additional information
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0011
(5Z)-3-amino-5-(3-hydroxy-2,4-diiodobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH 8.0, 25°C
0.0011
(5Z)-5-(2-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH 8.0, 25°C
0.0039
(5Z)-5-(2-methylbenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH 8.0, 25°C
0.0034
(5Z)-5-(3,4-dichlorobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH 8.0, 25°C
0.0018
(5Z)-5-(3-hydroxy-2,4-diiodobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH 8.0, 25°C
0.0006
(5Z)-5-(3-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH 8.0, 25°C
0.0047
(5Z)-5-(4-chlorobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH 8.0, 25°C
0.00004
2-nitrosofluorene
0.091
2-nitrosotoluene
0.237
4-nitrosobenzene
Homo sapiens
-
-
0.00006
4-nitrosobiphenyl
1.7 - 3.9
ATP
0.007
Benzyl isothiocyanate
Homo sapiens
-
at pH 7.5 and 37°C
0.1
cisplatin
0.03
N-(3-((2''-methoxyethyl)amino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.008
N-(3-(2''-chlorophenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0121
N-(3-(3'',5''-dimethylphenoxy)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0041
N-(3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0066
N-(3-(3'',5''-dimethylphenylamino)-5-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.03
N-(3-(3'',5''-dimethylphenylamino)-6-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide, N-(3-(3'',5''-dimethylphenylamino)-8-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0145
N-(3-(3''-chlorophenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.01 - 0.019
N-(3-(3''-formylphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzamide
-
0.0084
N-(3-(3''-formylphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0221
N-(3-(3''-formylphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)phenylacetamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0019
N-(3-(4''-bromophenoxy)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0009
N-(3-(4''-bromophenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0121
N-(3-(4''-chlorophenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0103
N-(3-(4''-formylphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.03
N-(3-(benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide, N-(3-(cyclopentylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0096
N-(3-(furan-2''-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.01
N-(3-(furan-3''-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0193
N-(3-(furan-3''-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)phenylacetamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0028
N-(3-phenoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0017
N-(3-phenylamino-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0042
N-(5-amino-3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0026
N-(7-amino-3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.00012
N-(8-amino-1,4-dioxo-3-(phenylamino)-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.00054
N-(8-amino-3-(3'',5''-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.03
N-(8-nitro-1,4-dioxo-3-(phenylamino)-1,4-dihydronaphthalen-2-yl)benzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0058
N-[3-(3,5-dimethylanilino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl]-N-methylbenzenesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0053
N-[3-(3,5-dimethylanilino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl]benzenesulfonamide
Homo sapiens
-
isoform NAT1, pH and temperature not specified in the publication
0.237
nitrosobenzene
Homo sapiens
-
HeLa cell NAT1
0.015
phenethyl isothiocyanate
Homo sapiens
-
at pH 7.5 and 37°C
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.000000002
isoform NAT 2, p-aminobenzoic acid, pH 7.4, 37°C
0.00000006
isoform NAT 2, procainamide, pH 7.4, 37°C
0.000000075
isoform NAT 2, 4-aminosalicylic acid, pH 7.4, 37°C
0.00000099
isoform NAT 2, 2-aminofluorene, pH 7.4, 37°C
0.00000189
isoform NAT 2, 5-aminosalicylic acid, pH 7.4, 37°C
0.00000241
isoform NAT 2, sulfamethazine, pH 7.4, 37°C
0.00000568
isoform NAT 1, procainamide, pH 7.4, 37°C
0.0000083
isoform NAT 1, sulfamethazine, pH 7.4, 37°C
0.0001
0.0002
0.0005
0.00052
isoform NAT 1, 2-aminofluorene, pH 7.4, 37°C
0.00058
isoform NAT 1, p-aminobenzoic acid, pH 7.4, 37°C
0.0006
0.0007
0.001
-
breast cancer cell line MCF-7, estrogen receptor (ER)-positive
0.00109
isoform NAT 1, 4-aminosalicylic acid, pH 7.4, 37°C
0.00117
isoform NAT 1, 5-aminosalicylic acid, pH 7.4, 37°C
0.0013
mutant GRSG
0.0014
mutant GRSG
0.00161
-
HeLa cell + N-acetyl-L-cysteine + 4-nitrosobiphenyl
0.00172
-
HeLa cell + 4-nitrosobiphenyl
0.0018
-
MCF-7 cell
0.0021
0.00408
-
in HeLa cells, substrate: p-aminosalicylic acid
0.0044
-
in HeLa cells, substrate: p-aminobenzoic acid
0.00454
-
HeLa cell + N-acetyl-L-cysteine
0.00466
-
HeLa cell
0.005
-
breast cancer cell line T47D, estrogen receptor (ER)-positive
0.0054
-
T-47D cell
0.0055
mutant GG
0.006
mutant GG
0.008
-
enzymatic activity found in peripheral blood mononuclear cell of investigated donors: 8-23.5 nmol/mg/min
0.0104
effect of androgen receptor expression in PC-3 cells, control, plus R1881
0.0105
-
enzymatic activity found in HepG2 cells
0.0109
effect of androgen receptor expression in PC-3 cells, plus pCMV-AR3.1, plus R1881
0.011
0.0113
effect of androgen receptor expression in PC-3 cells, control
0.0115
effect of androgen receptor expression in PC-3 cells, plus pCMV-AR3.1
0.014
HeLa cell
0.015
HeLa cell, treated with R1881
0.0234
-
enzymatic activity found in monocyte-derived dendritic cells of investigated donors: 23.4-26.6 nmol/mg/min
0.038
22Rv1 cell, plus R1881, plus flutamide
0.042
22Rv1 cell, plus DMSO
0.045
LNCaP cell
0.046
22Rv1 cells and LNCAP cells (both androgene-positive lines) show a high basal level of NAT1 activity between 46-51 nmol/min/mg protein
0.05
22Rv1 cell
0.054
-
cytokine mixture, 2.5 microM p-aminobenzoic acid
0.08
22Rv1 cell, plus R1881, 24h
0.097
-
cytokine mixture, 7.5 microM p-aminobenzoic acid
0.108
-
control, 2.5 microM p-aminobenzoic acid
0.124
-
cytokine mixture, 40 microM p-aminobenzoic acid
0.13
22Rv1 cell, treated with R1881
0.14
22Rv1 prostate cells upon treatment with 100 nmol of synthetic androgen R1881 for 24h
0.146
-
control, 7.5 microM p-aminobenzoic acid
0.2
-
control, 40 microM p-aminobenzoic acid
0.202
-
breast cancer cell line ZR-75-1, estrogen receptor (ER)-positive
0.2022
-
ZR-75-1 cell
0.237
-
recombinant NAT1, substrate: p-aminobenzoic acid
0.337
-
recombinant NAT1, substrate: p-aminosalicylic acid
0.55
-
-
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
pI: 4.8
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
30 - 33
mutant GG
30 - 50
control
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
healthy and neoplastic tissue
Manually annotated by BRENDA team
patients with ductal carcinoma
Manually annotated by BRENDA team
isozyme NAT2 mainly
Manually annotated by BRENDA team
-
type II alveolar cell, presence of isoform Nat1. Exposure of cells to pathophysiologically relevant amounts of oxidants such as H2O2 or peroxyntrite, impairs the cellular biotransformation of aromatic amines
Manually annotated by BRENDA team
healthy and neoplastic tissue
Manually annotated by BRENDA team
-
presence of isoform Nat1. Exposure of cells to pathophysiologically relevant amounts of oxidants such as H2O2 or peroxyntrite, impairs the cellular biotransformation of aromatic amines
Manually annotated by BRENDA team
-
presence of isoform Nat1. Exposure of cells to pathophysiologically relevant amounts of oxidants such as H2O2 or peroxyntrite, impairs the cellular biotransformation of aromatic amines
Manually annotated by BRENDA team
NAT1-specific protein expression is higher in CD3+ cells than in CD19 or CD56 cells
Manually annotated by BRENDA team
NAT1-specific protein expression is higher in CD3+ cells than in CD19 or CD56 cells
Manually annotated by BRENDA team
NAT1-specific protein expression is higher in CD3+ cells than in CD19 or CD56 cells
Manually annotated by BRENDA team
-
isoform NAT2
Manually annotated by BRENDA team
-
high activity of isozyme NAT1
Manually annotated by BRENDA team
a cholangiocarcinoma cell line, isozyme NAT1
Manually annotated by BRENDA team
-
expressed in placenta during the first trimester of embryonic development
Manually annotated by BRENDA team
-
androgen-dependent expression of NAT1 is demonstrated
Manually annotated by BRENDA team
NAT1 is strongly localized to androgen-positive epithelium in human prostate
Manually annotated by BRENDA team
-
both NAT2 mRNA and enzyme are readily detected in fetal, newborn, and adult muscles. High expression in fetal muscle. Despite the presence of its mRNA, NAT2 enzyme level is below the limit of detection
Manually annotated by BRENDA team
-
high activity of isozyme NAT1
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
ARY2_HUMAN
290
1
33571
Swiss-Prot
other Location (Reliability: 1)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
26500
-
gel filtration
31000
-
1 * 31000, SDS-PAGE
33000
33840
-
mass spectrometry
34000
-
x * 34000, SDS-PAGE
35000
-
HeLa cell NAT1, determined by SDS-PAGE and Western blot analysis
37000
-
recombinant NAT1, determined by SDS-PAGE and Western blot analysis
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
monomer
-
1 * 31000, SDS-PAGE
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
acetylation
lysine 100 is a site of posttranslational modification by acetylation
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
in complex with coenzyme A
high resolution crystal structures of both human NATs, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a site-directed NAT1 mutant, NAT1-F125S, and a NAT2-CoA complex are presented. By comparing the structures with known prokaryotic structures, evidences are provided for novel structural features of human NATs that are absent in bacterial enzymes, including an insertion that produces a significant difference in the structure of the carboxyl terminus of the eukaryotic enzymes
-
high resolution crystal structures of both human NATs, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a site-directed NAT1 mutant, NAT1-F125S, and a NAT2-CoA complex are presented. By comparing the structures with known prokaryotic structures, evidences are provided for novel structural features of human NATs that are absent in bacterial enzymes, including an insertion that produces a significant difference in the structure of the carboxyl terminus of the eukaryotic enzymes. A complete picture of the distinct substrate selectivity of human NAT1 and NAT2, as well as key features of the naturally occurring variants of NAT1 and NAT2 is provided
-
in complex with 2-bromoacetanilide
modelling predicts that ATP binds within the active site cleft arranged with the triphosphate group in close proximity to arginine 127
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
A434C
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
A752T
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
A803G
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
C190T
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
C559T
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
C97T
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
D122N
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR
E167K
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR. Reduction in maximum activity
E8G
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
F192Y
site-directed mutagenesis, the NAT2 mutant shows highly reduced activity compared to the wild-type enzyme
G191A
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
G286E
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR. Reduction in maximum activity
G364A
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
G499A
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
G560A
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
G590A
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
G857A
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
H43R
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
I114T
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR. Reduction in both N- and O-acetyltransferase catalytic activitiy
I32V
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
K13R
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
K141E
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
K268R
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR
K282T
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR
L137F
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR
L239F
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
L69P
site-directed mutagenesis, the NAT2 mutant shows highly reduced activity compared to the wild-type enzyme
L74P
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
Q133R
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
Q145P
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR. Reduction in both N- and O-acetyltransferase catalytic activitiy
R197Q
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR. Reduction in both N- and O-acetyltransferase catalytic activitiy. Reduction in maximum activity
R64W
single nucleotide polymorphism, evaluation of functional effect based on crystal strucutre, PDB 2PFR. Reduction in both N- and O-acetyltransferase catalytic activitiy
S102C
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
T250P
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
T341C
single nucleotide polymorphism (SNP) found in human, resulting in a decreased activity of enzyme
Y190C
site-directed mutagenesis, the NAT2 mutant shows highly reduced activity compared to the wild-type enzyme
Y190F
site-directed mutagenesis, the NAT2 mutant shows reduced activity compared to the wild-type enzyme
A54V
-
activity with 2-aminofluorene is about 10% of the wild-type activity
C190T
-
NAT2 single nucleotide polymorphism
C223G
-
NAT2, enzymatically active, markedly reduced in vitro stability
C44G
-
NAT2, enzymatically active, markedly reduced in vitro stability
C481T
-
NAT2 single nucleotide polymorphism
D251G
-
activity with 2-aminofluorene is about 15% of the wild-type activity
E203D
-
609T, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
E264K
F125S
F202L
-
activity with 2-aminofluorene is about 20% of the wild-type activity
G191A
-
NAT2 single nucleotide polymorphism
G286E
-
857A, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
G590A
-
NAT2 single nucleotide polymorphism
G857A
-
NAT2 single nucleotide polymorphism
I114T
-
341C, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
I238T
-
activity with 2-aminofluorene is about 30% of the wild-type activity, the KM-value for 2-aminofluorene is 1.3fold higher than the wild-type value
K100E
-
the mutation significantly increases the Ka value for acetyl-CoA without changing the Kb value for the acetyl acceptor 4-aminobenzoate
K100L
-
the mutation significantly increases the Ka value for acetyl-CoA without changing the Kb value for the acetyl acceptor 4-aminobenzoate
K100Q
mutation decreases the potency of ATP as an inhibitor of NAT1. The Hill coefficient increases twofold
K100R
K185N
-
activity with 2-aminofluorene is about 35% of the wild-type activity, the KM-value for 2-aminofluorene is 1.5fold higher than the wild-type value
K268R
-
803G, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
L135V
-
403G, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
L181A
-
activity with 2-aminofluorene is about 80% of the wild-type activity
L194R
-
activity with 2-aminofluorene is about 30% of the wild-type activity
L24I
-
70A, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
L40H
-
activity with 2-aminofluorene is about 5% of the wild-type activity
M205V
-
activity with 2-aminofluorene is about 40% of the wild-type activity
N172I
-
activity with 2-aminofluorene is about 20% of the wild-type activity, the KM-value for 2-aminofluorene is 3.6fold higher than the wild-type value
N245I
NAT2*12A.U4
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*13.U1
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*4.U1
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*4.U2
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*4.U3
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*4.U5
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*4.U6
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*4.U7
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*5B.U1
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*5B.U4
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*6A.U1
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*7B.U2
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
NAT2*7B.U3
-
polymorphism, proposed new nomenclature composed of haplotype in the promoter region and conventional NAT2 haplotype in the coding region
P228L
-
683T, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
P96L
-
activity with 2-aminofluorene is slightly higher than wild-type activity
Q226R
-
activity with 2-aminofluorene is about 15% of the wild-type activity
R127S
-
mutant shows a 42fold decreased affinity for the NAT1-selective substrate p-aminobenzoic acid
R197Q
-
590A, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
R242M
single nucleotide variant, identified within a South African mixed ancestry population, displays a similar profile to the published variant, I263V (proposed fast acetylator), and the wild-type protein structure
R64Q
-
191A, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
S125F/S127R/S129Y
-
mutation of all three Ser residues 125, 127 and 129 to those normally present in NAT1 is required to produce the low affinity for sulfamethazine approximating that of native NAT1
T198A
-
activity with 2-aminofluorene is about 50% of the wild-type activity
T207S
-
activity with 2-aminofluorene is slightly higher than wild-type activity
T341C
-
NAT2 single nucleotide polymorphism
V146A
-
activity with 2-aminofluorene is about 50% of the wild-type activity
V231G
V280M
-
838A, single nucleotide polymorphism, point mutation in the arylamine N-acetyltransferase 2 gene, effect missense
W77R
-
activity with 2-aminofluorene is about 25% of the wild-type activity, the KM-value for 2-aminofluorene is 1.3fold higher than the wild-type value
additional information
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
37
-
t1/2: 35 h NAT2 wild-type, 3.5 h Cys44Gly-mutant, 0.5 h Cys223Gly-mutant
37 - 47
-
NAT1 is sensitive to heat denaturation and shows a significant loss in activity as temperature is increased from 37°C to 47°C
40 - 47
-
NAT enzymes unfold cooperatively with concomitant loss of activity at 40-47°C
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
2-mercaptoethanol stabilizes
-
cysteine stabilizes
-
glycerol and albumin stabilize
-
thioglycolate stabilizes
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-60°C, 60-80% loss of activity after 3 weeks
-
-60°C, at least 3 weeks in the presence of 2-mercaptoethanol, thioglycolate or cysteine
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
native enzyme partially by subcellular fractionation
Ni-NTA resin column chromatography, and gel filtration
by using chromatographic purification. Yield: 2.8 mg of homogeneous NAT2 from 2 L of cell culture
-
His-select nickel resin column chromatography
-
native enzyme partially by subcellular fractionation
Ni-NTA affinity column chromatography, and gel filtration
-
Ni-NTA column chromatography
-
recombinant His-tagged isozyme NAT1 from Escherichia coli strain BL21(DE3) by nickel affinity chromatography
recombinant wild-type and mutant NAT1 from Escherichia coli
using Ni-NTA chromatography
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli BL21(DE3)CodonPlus-RIL cells
expression in Escherichia coli
isozyme NAT2, DNA and amino acid sequence determination and analysis, expression of wild-type and mutants in Escherichia coli strain JM105
isozyme NAT2, expression in Escherichia coli strain DJ2002
2 genes, NAT1 and 2, encoding enzyme proteins, transiently expressed in cultured monkey kidney COS-1 cells
-
a series of constructs is cloned into the pGL3-enhancer
expressed as a His-tagged fusion protein in Escherichia coli
-
expressed in Escherichia coli as a His-tagged fusion protein
-
expressed in Escherichia coli BL21(DE3) cells
-
expressed in Escherichia coli JM105 cells
-
expressed in Escherichia coli Rosetta(DE3)pLysS cells
-
expression in Escherichia coli
expression in HeLa cell
expression of His-tagged isozyme NAT1 in Escherichia coli strain BL21(DE3)
expression of wild-type and mutant NAT1 in Escherichia coli
gene NAT1, DNA and amino acid sequence determination and analysis, genetic organization, several splice variants of the NAT1 gene that are expressed from different promoters, expression analysis, the NAT1 gene is located on chromosome 8 at 8p21-22, a region known to be deleted in many human cancers
gene NAT1, DNA and amino acid sequence determnination and analysis, quantitative expression analysis
human NAT1 and NAT2 genes located on chromosome 8p22
-
human wild-type NAT2 is overexpressed as a dihydrofolate reductase fusion protein containing a TEV protease-sensitive linker
-
into the pET28a vector for expression in Escherichia coli BL21DE3 cells
-
into the pKK223-3 bacterial expression vector for transformation of Escherichia coli JM105 cells
NAT1 and NAT2, expressed in Escherichia coli XA90
-
NAT1 is recombinantly expressed
-
NAT1, DNA and amino acid sequence determination and analysis, exon composition, expression analysis, identification of an alternative NAT1 promoter lying 51.5 kb upstream of the NAT1 ORF, all NAT1 P3 mRNAs included 5'-untranslated region internal exons of 61 and 175 nucleotides in addition to the 79 nucleotide 5'-untranslated region exon present in P1 mRNA CAP-dependent amplification of 50-P3 mRNA termini defined an 84 base pair transcription start region in which most start sites are centrally clustered, overview
-
over-expressed in Salmonella typhimurium umu strain
-
overexpression in Escherichia coli
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
alpha-solanine can decrease the expression of both NAT1 mRNA and NAT2 mRNA
5-fluorouracil decreases N-acetyltransferase expression
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
inhibitors of NAT enzymes may be valuable as chemopreventive agents
medicine
analysis
the NAT enzyme activates an arylhydroxamic acid functionality into a nitrenium ion that reacts fast, covalently, and under neutral conditions with nucleophilic residues of neighboring proteins. Strong labeling is only observed with an arylhydroxamic acid bearing an electron donating substituent. Clear labeling is achieved on a subcellular level in living cells that are transfected with a genetically targeted NAT to the nucleus or the cytosol
drug development
inhibitors of NAT enzymes may be valuable as chemopreventive agents
medicine
molecular biology
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Grant, D.M.; Blum, M.; Beer, M.; Meyer, U.A.
Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes
Mol. Pharmacol.
39
184-191
1991
Homo sapiens
Manually annotated by BRENDA team
Gollamudi, R.; Rackley, R.J.; Autian, J.
A new substrate for the measurement of N-acetyltransferase activity
Enzyme
30
155-161
1983
Oryctolagus cuniculus, Homo sapiens, Mus musculus, no activity in Canis familiaris, Rattus norvegicus
Manually annotated by BRENDA team
Weber, W.W.
N-Acetyltransferase (mammalian liver)
Methods Enzymol.
17B
805-811
1971
Oryctolagus cuniculus, Homo sapiens, Platyrrhini, Rattus norvegicus
-
Manually annotated by BRENDA team
Schulte, E.H.; Schloot, W.; Goedde, H.W.
Purification of human liver serotonin/isoniazid N-acetyltransferase by preparative polyacrylamide gel elctrophoresis and determination of molecular weight
Z. Naturforsch. C
29c
661-666
1974
Homo sapiens
-
Manually annotated by BRENDA team
Dupret, J.M.; Grant, D.M.
Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2
J. Biol. Chem.
267
7381-7385
1992
Homo sapiens
Manually annotated by BRENDA team
Grant, D.M.; Lottspeich, F.; Meyer, U.A.
Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver
FEBS Lett.
244
203-207
1989
Homo sapiens
Manually annotated by BRENDA team
Hein, D.W.
Acetylator genotype and arylamine-induced carcinogenesis
Biochim. Biophys. Acta
948
37-66
1988
Homo sapiens, Mesocricetus auratus, Mus musculus, no activity in Canis familiaris, Oryctolagus cuniculus, Salmonella enterica subsp. enterica serovar Typhimurium
Manually annotated by BRENDA team
Hickman, D.; Palamanda, J.R.; Unadkat, J.D.; Sim, E.
Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli
Biochem. Pharmacol.
50
697-703
1995
Homo sapiens
Manually annotated by BRENDA team
Butcher, N.J.; Ilett, K.F.; Minchin, R.F.
Inactivation of human arylamine N-acetyltransferase 1 by the hydroxylamine of p-Aminobenzoic acid
Biochem. Pharmacol.
60
1829-1836
2000
Homo sapiens
Manually annotated by BRENDA team
Yeh, C.C.; Hung, C.F.; Wang, W.L.; Chung, J.G.
Kinetics of acetyl coenzyme A: arylamine N-acetyltransferase from rapid and slow acetylator human benign prostatic hyperplasia tissues
Urol. Res.
29
311-316
2001
Homo sapiens
Manually annotated by BRENDA team
Goodfellow, G.H.; Dupret, J.M.; Grant, D.M.
Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2
Biochem. J.
348
159-166
2000
Homo sapiens
-
Manually annotated by BRENDA team
Chung, J.G.; Chen, G.W.; Yeh, H.N.; Hung, C.F.; Huang, D.S.
Kinetics of acetyl coenzyme A:arylamine N-acetyltransferase from the human umbilical cord
Res. Commun. Pharmacol. Toxicol.
2
193-204
1997
Homo sapiens
-
Manually annotated by BRENDA team
Palamanda, J.R.; Hickman, D.; Ward, A.; Sim, E.; Romkes-Sparks, M.; Unadkat, J.D.
Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs
Drug Metab. Dispos.
23
473-477
1995
Homo sapiens
Manually annotated by BRENDA team
Sekine, A.; Saito, S.; Iida, A.; Mitsunobu, Y.; Higuchi, S.; Harigae, S.; Nakamura, Y.
Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1, and L1CAM in the Japanese population
Hum. Genet.
46
314-319
2001
Saccharomyces cerevisiae, Homo sapiens
Manually annotated by BRENDA team
Dairou, J.; Atmane, N.; Dupret, J.M.; Rodrigues-Lima, F.
Reversible inhibition of the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 by S-nitrosothiols
Biochem. Biophys. Res. Commun.
307
1059-1065
2003
Homo sapiens
Manually annotated by BRENDA team
Winter, H.R.; Unadkat, J.D.
Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism
Drug Metab. Dispos.
33
969-976
2005
Homo sapiens
Manually annotated by BRENDA team
Atmane, N.; Dairou, J.; Paul, A.; Dupret, J.M.; Rodrigues-Lima, F.
Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1). Reversible inactivation by hydrogen peroxide
J. Biol. Chem.
278
35086-35092
2003
Homo sapiens
Manually annotated by BRENDA team
Dairou, J.; Atmane, N.; Rodrigues-Lima, F.; Dupret, J.M.
Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: a cellular and mechanistic study
J. Biol. Chem.
279
7708-7714
2004
Homo sapiens
Manually annotated by BRENDA team
Rodrigues-Lima, F.; Cooper, R.N.; Goudeau, B.; Atmane, N.; Chamagne, A.M.; Butler-Browne, G.; Sim, E.; Vicart, P.; Dupret, J.M.
Skeletal muscles express the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase
J. Histochem. Cytochem.
51
789-796
2003
Homo sapiens
Manually annotated by BRENDA team
Summerscales, J.E.; Josephy, P.D.
Human acetyl CoA:arylamine N-acetyltransferase variants generated by random mutagenesis
Mol. Pharmacol.
65
220-226
2004
Homo sapiens
Manually annotated by BRENDA team
Wang, H.; Vath, G.M.; Kawamura, A.; Bates, C.A.; Sim, E.; Hanna, P.E.; Wagner, C.R.
Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1
Protein J.
24
65-77
2005
Homo sapiens
Manually annotated by BRENDA team
Delomenie, C.; Fouix, S.; Longuemaux, S.; Brahimi, N.; Bizet, C.; Picard, B.; Denamur, E.; Dupret, J.M.
Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid
J. Bacteriol.
183
3417-3427
2001
Achromobacter xylosoxidans, Achromobacter xylosoxidans 71.32, Aeromonas hydrophila, Aeromonas hydrophila 76.14, Bacteroides sp., Bacteroides sp. 100, Citrobacter amalonaticus, Citrobacter amalonaticus 82.89, Citrobacter farmeri, Citrobacter farmeri 104553, Citrobacter freundii, Citrobacter freundii 57.32, Citrobacter koseri, Citrobacter koseri 82.94, Escherichia coli, Escherichia coli 54.8, Escherichia coli K-12 MG1655, Helicobacter pylori, Helicobacter pylori 43579, Homo sapiens (P11245), Homo sapiens (P18440), Homo sapiens, Klebsiella oxytoca, Klebsiella oxytoca 103434, Klebsiella pneumoniae, Klebsiella pneumoniae 82.91, Klebsiella pneumoniae subsp. ozaenae, Klebsiella pneumoniae subsp. ozaenae 52.211, Klebsiella pneumoniae subsp. rhinoscleromatis, Klebsiella pneumoniae subsp. rhinoscleromatis 52.210, Morganella morganii, Morganella morganii A.231, Pasteurella multocida, Pasteurella multocida 103286, Plesiomonas shigelloides, Plesiomonas shigelloides 63.5, Proteus vulgaris, Proteus vulgaris 58.60, Providencia alcalifaciens, Providencia alcalifaciens 82.90, Pseudomonas aeruginosa, Pseudomonas aeruginosa 100720, Salmonella enterica subsp. enterica serovar Typhimurium, Serratia marcescens, Serratia marcescens 103235, Shigella flexneri, Shigella flexneri 82.48, Vibrio cholerae serotype O1, Vibrio cholerae serotype O1 54.315
Manually annotated by BRENDA team
Rodrigues-Lima, F.; Dupret, J.M.
3D Model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop
Biochem. Biophys. Res. Commun.
291
116-123
2002
Homo sapiens (P11245), Homo sapiens
Manually annotated by BRENDA team
Butcher, N.J.; Tetlow, N.L.; Cheung, C.; Broadhurst, G.M.; Minchin, R.F.
Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells
Cancer Res.
67
85-92
2007
Homo sapiens, Homo sapiens (P18440)
Manually annotated by BRENDA team
Walraven, J.M.; Trent, J.O.; Hein, D.W.
Computational and eperimental aalyses of mammalian arylamine N-acetyltransferase structure and function
Drug Metab. Dispos.
35
1001-1007
2007
Homo sapiens, Homo sapiens (P11245), Homo sapiens (P18440)
Manually annotated by BRENDA team
Lee, Y.; Wu, T.
Effects of 5-methoxypsoralen (5-MOP) on arylamine N-acetyltransferase activity in the stomach and colon of rats and human stomach and colon tumor cell lines
In Vivo
19
1061-1070
2005
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Minchin, R.F.; Hanna, P.E.; Dupret, J.M.; Wagner, C.R.; Rodrigues-Lima, F.; Butcher, N.J.
Molecules in focus. Arylamine N-acetyltransferase I
Int. J. Biochem. Cell Biol.
39
1999-2005
2007
Homo sapiens, Homo sapiens (P18440)
Manually annotated by BRENDA team
Liu, F.; Zhang, N.; Zhou, X.; Hanna, P.E.; Wagner, C.R.; Koepp, D.M.; Walters, K.J.
Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation
J. Mol. Biol.
361
482-492
2006
Homo sapiens (P11245), Homo sapiens (P18440), Homo sapiens, Mesocricetus auratus (P50292), Mesocricetus auratus (P50293)
Manually annotated by BRENDA team
Zhang, N.; Liu, L.; Liu, F.; Wagner, C.R.; Hanna, P.E.; Walters, K.J.
NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity
J. Mol. Biol.
363
188-200
2006
Homo sapiens (P11245), Homo sapiens (P18440), Homo sapiens, Mesocricetus auratus (P50293)
Manually annotated by BRENDA team
Savulescu, M.R.; Mushtaq, A.; Josephy, P.D.
Screening and characterizing human NAT2 variants
Methods Enzymol.
400
192-215
2005
Homo sapiens (P11245), Homo sapiens
Manually annotated by BRENDA team
Dupret, J.M.; Dairou, J.; Atmane, N.; Rodrigues-Lima, F.
Inactivation of human arylamine N-acetyltransferase 1 by hydrogen peroxide and peroxynitrite
Methods Enzymol.
400
215-229
2005
Homo sapiens (P11245), Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Geylan-Su, Y.S.; Isgoer, B.; Coban, T.; Kapucuoglu, N.; Aydintug, S.; Iscan, M.; Iscan, M.; Gueray, T.
Comparison of NAT1, NAT2 and GSTT2-2 activities in normal and neoplastic human breast tissues
Neoplasma
53
73-78
2006
Homo sapiens (P11245), Homo sapiens (P18440)
Manually annotated by BRENDA team
Barker, D.F.; Husain, A.; Neale, J.R.; Martini, B.D.; Zhang, X.; Doll, M.A.; States, J.C.; Hein, D.W.
Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1
Pharmacogenet. Genomics
16
515-525
2006
Homo sapiens
Manually annotated by BRENDA team
Kukongviriyapan, V.; Phromsopha, N.; Tassaneeyakul, W.; Kukongviriyapan, U.; Sripa, B.; Hahnvajanawong, V.; Bhudhisawasdi, V.
Inhibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2
Xenobiotica
36
15-28
2006
Homo sapiens (P11245), Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Liu, L.; Von Vett, A.; Zhang, N.; Walters, K.J.; Wagner, C.R.; Hanna, P.E.
Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2
Chem. Res. Toxicol.
20
1300-1308
2007
Homo sapiens
Manually annotated by BRENDA team
Liu, L.; Wagner, C.R.; Hanna, P.E.
Human Arylamine N-Acetyltransferase 1: In Vitro and Intracellular Inactivation by Nitrosoarene Metabolites of Toxic and Carcinogenic Arylamines
Chem. Res. Toxicol.
21
2005-2016
2008
Homo sapiens
Manually annotated by BRENDA team
Grant, D.M.
Structures of human arylamine N-acetyltransferases
Curr. Drug Metab.
9
465-470
2008
Homo sapiens, Mesocricetus auratus
Manually annotated by BRENDA team
Sim, E.; Sandy, J.; Evangelopoulos, D.; Fullam, E.; Bhakta, S.; Westwood, I.; Krylova, A.; Lack, N.; Noble, M.
Arylamine N-acetyltransferases in mycobacteria
Curr. Drug Metab.
9
510-519
2008
Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium tuberculosis variant bovis, Mycobacterium marinum, Rhodococcus, Mycolicibacterium vanbaalenii, Mycobacterium ulcerans, Mycobacterium sp. MCS, Mycobacterium sp. KMS, Mycobacterium sp. JLS, Mycolicibacterium gilvum, Mycobacterium tuberculosis variant bovis BCG, Mycolicibacterium smegmatis (O86309), Mycolicibacterium smegmatis, Homo sapiens (P11245), Homo sapiens, Mycobacterium ulcerans Agy99, Mycolicibacterium vanbaalenii PYR-1, Mycolicibacterium gilvum PYR-GCK, Rhodococcus RHA1
Manually annotated by BRENDA team
Makarova, S.I.
Human N-acetyltransferases and drug-induced hepatotoxicity
Curr. Drug Metab.
9
538-545
2008
Homo sapiens
Manually annotated by BRENDA team
Sim, E.; Walters, K.; Boukouvala, S.
Arylamine N-acetyltransferases: from structure to function
Drug Metab. Rev.
40
479-510
2008
Homo sapiens (P11245)
Manually annotated by BRENDA team
Kubota, R.; Ohno, M.; Hasunuma, T.; Iijima, H.; Azuma, J.
Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2
Eur. J. Clin. Pharmacol.
63
927-933
2007
Homo sapiens
Manually annotated by BRENDA team
Possuelo, L.G.; Castelan, J.A.; de Brito, T.C.; Ribeiro, A.W.; Cafrune, P.I.; Picon, P.D.; Santos, A.R.; Teixeira, R.L.; Gregianini, T.S.; Hutz, M.H.; Rossetti, M.L.; Zaha, A.
Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil
Eur. J. Clin. Pharmacol.
64
673-681
2008
Homo sapiens (P11245)
Manually annotated by BRENDA team
Sim, E.; Westwood, I.; Fullam, E.
Arylamine N-acetyltransferases
Expert. Opin. Drug Metab. Toxicol.
3
169-184
2007
Canis lupus familiaris, Homo sapiens, Mesocricetus auratus, Mus musculus, Mycobacterium tuberculosis variant bovis, Mus spretus
Manually annotated by BRENDA team
Wakefield, L.; Robinson, J.; Long, H.; Ibbitt, J.C.; Cooke, S.; Hurst, H.C.; Sim, E.
Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors
Genes Chromosomes Cancer
47
118-126
2008
Homo sapiens
Manually annotated by BRENDA team
Wu, H.; Dombrovsky, L.; Tempel, W.; Martin, F.; Loppnau, P.; Goodfellow, G.H.; Grant, D.M.; Plotnikov, A.N.
Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases
J. Biol. Chem.
282
30189-30197
2007
Homo sapiens
Manually annotated by BRENDA team
Yuliwulandari, R.; Sachrowardi, Q.; Nishida, N.; Takasu, M.; Batubara, L.; Susmiarsih, T.P.; Rochani, J.T.; Wikaningrum, R.; Miyashita, R.; Miyagawa, T.; Sofro, A.S.; Tokunaga, K.
Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature
J. Hum. Genet.
53
201-209
2008
Homo sapiens
Manually annotated by BRENDA team
Roemer, H.C.; Weistenhofer, W.; Lohlein, D.; Geller, F.; Blomeke, B.; Golka, K.
N-acetyltransferase 1 in colon and rectal cancer cases from an industrialized area
J. Toxicol. Environ. Health Part A
71
902-905
2008
Homo sapiens
Manually annotated by BRENDA team
Lichter, J.; Heckelen, A.; Fischer, K.; Blomeke, B.
Expression of N-acetyltransferase in monocyte-derived dendritic cells
J. Toxicol. Environ. Health Part A
71
960-964
2008
Homo sapiens
Manually annotated by BRENDA team
Fukino, K.; Sasaki, Y.; Hirai, S.; Nakamura, T.; Hashimoto, M.; Yamagishi, F.; Ueno, K.
Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients
J. Toxicol. Sci.
33
187-195
2008
Homo sapiens
Manually annotated by BRENDA team
Ragunathan, N.; Dairou, J.; Pluvinage, B.; Martins, M.; Petit, E.; Janel, N.; Dupret, J.M.; Rodrigues-Lima, F.
Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition
Mol. Pharmacol.
73
1761-1768
2008
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Teixeira, R.L.; Miranda, A.B.; Pacheco, A.G.; Lopes, M.Q.; Fonseca-Costa, J.; Rabahi, M.F.; Melo, H.M.; Kritski, A.L.; Mello, F.C.; Suffys, P.N.; Santos, A.R.
Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil
Mutat. Res.
624
31-40
2007
Homo sapiens
Manually annotated by BRENDA team
Oda, Y.; Watanabe, T.; Terao, Y.; Nukaya, H.; Wakabayashi, K.
Genotoxic activation of 2-phenylbenzotriazole-type compounds by human cytochrome P4501A1 and N-acetyltransferase expressed in Salmonella typhimurium umu strains
Mutat. Res.
654
52-57
2008
Homo sapiens
Manually annotated by BRENDA team
Kim, S.J.; Kang, H.S.; Chang, H.L.; Jung, Y.C.; Sim, H.B.; Lee, K.S.; Ro, J.; Lee, E.S.
Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer
Oncol. Rep.
19
663-668
2008
Homo sapiens
Manually annotated by BRENDA team
Hein, D.W.; Boukouvala, S.; Grant, D.M.; Minchin, R.F.; Sim, E.
Changes in consensus arylamine N-acetyltransferase gene nomenclature
Pharmacogenet. Genomics
18
367-368
2008
Gallus gallus, Oryctolagus cuniculus, Homo sapiens, Mesocricetus auratus, Mus musculus, Rattus norvegicus
Manually annotated by BRENDA team
Buranrat, B.; Prawan, A.; Sripa, B.; Kukongviriyapan, V.
Inflammatory cytokines suppress arylamine N-acetyltransferase 1 in cholangiocarcinoma cells
World J. Gastroenterol.
13
6219-6225
2007
Homo sapiens
Manually annotated by BRENDA team
Takubo, K.; Tsuchiya, H.; Kurimasa, A.; Arnesen, T.; Ryoke, K.; Shiota, G.
Involvement of N-acetyltransferase human in the cytotoxic activity of 5-fluorouracil
Anticancer Drugs
20
668-675
2009
Homo sapiens
Manually annotated by BRENDA team
Tiang, J.M.; Butcher, N.J.; Minchin, R.F.
Small molecule inhibition of arylamine N-Acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells
Biochem. Biophys. Res. Commun.
393
95-100
2010
Homo sapiens
Manually annotated by BRENDA team
Russell, A.J.; Westwood, I.M.; Crawford, M.H.; Robinson, J.; Kawamura, A.; Redfield, C.; Laurieri, N.; Lowe, E.D.; Davies, S.G.; Sim, E.
Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2
Bioorg. Med. Chem.
17
905-918
2009
Homo sapiens
Manually annotated by BRENDA team
Mitchell, D.J.; Minchin, R.F.
E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2
Cancer Gene Ther.
15
758-764
2008
Homo sapiens
Manually annotated by BRENDA team
Guilhen, A.C.; Bufalo, N.E.; Morari, E.C.; Leite, J.L.; Assumpcao, L.V.; Tincani, A.J.; Ward, L.S.
Role of the N-acetyltransferase 2 detoxification system in thyroid cancer susceptibility
Clin. Cancer Res.
15
406-412
2009
Homo sapiens
Manually annotated by BRENDA team
Walraven, J.M.; Trent, J.O.; Hein, D.W.
Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1
Drug Metab. Rev.
40
169-184
2008
Homo sapiens (P11245)
Manually annotated by BRENDA team
Erickson, R.; Cao, W.; Acuna, D.; Strnatka, D.; Hunter, R.; Chau, B.; Wakefield, L.; Sim, E.; Mcqueen, C.
Confirmation of the role of N-acetyltransferase 2 in teratogen-induced cleft palate using transgenics and knockouts
Mol. Reprod. Dev.
75
1071-1076
2008
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Dairou, J.; Petit, E.; Ragunathan, N.; Baeza-Squiban, A.; Marano, F.; Dupret, J.M.; Rodrigues-Lima, F.
Arylamine N-acetyltransferase activity in bronchial epithelial cells and its inhibition by cellular oxidants
Toxicol. Appl. Pharmacol.
236
366-371
2009
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Rawal, J.; Jones, R.; Payne, A.; Gardner, I.
Strategies to prevent N-acetyltransferase-mediated metabolism in a series of piperazine-containing pyrazalopyrimidine compounds
Xenobiotica
38
1219-1239
2008
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Laurieri, N.; Dairou, J.; Egleton, J.E.; Stanley, L.A.; Russell, A.J.; Dupret, J.M.; Sim, E.; Rodrigues-Lima, F.
From arylamine N-acetyltransferase to folate-dependent acetyl CoA hydrolase: impact of folic acid on the activity of (HUMAN)NAT1 and its homologue (MOUSE)NAT2
PLoS ONE
9
e96370
2014
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Stepp, M.W.; Mamaliga, G.; Doll, M.A.; States, J.C.; Hein, D.W.
Folate-dependent hydrolysis of acetyl-coenzyme A by recombinant human and rodent arylamine N-acetyltransferases
Biochem. Biophys. Rep.
3
45-50
2015
Homo sapiens
Manually annotated by BRENDA team
Minchin, R.F.; Butcher, N.J.
The role of lysine(100) in the binding of acetylcoenzyme A to human arylamine N-acetyltransferase 1: implications for other acetyltransferases
Biochem. Pharmacol.
94
195-202
2015
Homo sapiens
Manually annotated by BRENDA team
Egleton, J.E.; Thinnes, C.C.; Seden, P.T.; Laurieri, N.; Lee, S.P.; Hadavizadeh, K.S.; Measures, A.R.; Jones, A.M.; Thompson, S.; Varney, A.; Wynne, G.M.; Ryan, A.; Sim, E.; Russell, A.J.
Structure-activity relationships and colorimetric properties of specific probes for the putative cancer biomarker human arylamine N-acetyltransferase 1
Bioorg. Med. Chem.
22
3030-3054
2014
Homo sapiens
Manually annotated by BRENDA team
Endo, Y.; Yamashita, H.; Takahashi, S.; Sato, S.; Yoshimoto, N.; Asano, T.; Hato, Y.; Dong, Y.; Fujii, Y.; Toyama, T.
Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer
BMC Cancer
14
990
2015
Homo sapiens
Manually annotated by BRENDA team
Laurieri, N.; Kawamura, A.; Westwood, I.M.; Varney, A.; Morris, E.; Russell, A.J.; Stanley, L.A.; Sim, E.
Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding
BMC Pharmacol. Toxicol.
15
68
2014
Homo sapiens (P11245), Homo sapiens
Manually annotated by BRENDA team
Sim, E.; Abuhammad, A.; Ryan, A.
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery
Br. J. Pharmacol.
171
2705-2725
2014
Homo sapiens
Manually annotated by BRENDA team
Deng, Z.J.; Butcher, N.J.; Mortimer, G.M.; Jia, Z.; Monteiro, M.J.; Martin, D.J.; Minchin, R.F.
Interaction of human arylamine N-acetyltransferase 1 with different nanomaterials
Drug Metab. Dispos.
42
377-383
2014
Homo sapiens
Manually annotated by BRENDA team
Kubiak, X.; Dairou, J.; Dupret, J.M.; Rodrigues-Lima, F.
Crystal structure of arylamine N-acetyltransferases: insights into the mechanisms of action and substrate selectivity
Expert. Opin. Drug Metab. Toxicol.
9
349-362
2013
Mycobacterium marinum (B2HIZ6), Mycolicibacterium smegmatis (O86309), Homo sapiens (P11245), Homo sapiens (P18440), Salmonella enterica subsp. enterica serovar Typhimurium (Q00267), Bacillus cereus (Q81AS3), Bacillus anthracis (Q81R98), Mesorhizobium loti (Q98D42)
Manually annotated by BRENDA team
Duval, R.; Xu, X.; Bui, L.C.; Mathieu, C.; Petit, E.; Cariou, K.; Dodd, R.H.; Dupret, J.M.; Rodrigues-Lima, F.
Identification of cancer chemopreventive isothiocyanates as direct inhibitors of the arylamine N-acetyltransferase-dependent acetylation and bioactivation of aromatic amine carcinogens
Oncotarget
7
8688-8699
2016
Homo sapiens
Manually annotated by BRENDA team
Laurieri, N.; Egleton, J.E.; Varney, A.; Thinnes, C.C.; Quevedo, C.E.; Seden, P.T.; Thompson, S.; Rodrigues-Lima, F.; Dairou, J.; Dupret, J.M.; Russell, A.J.; Sim, E.
A novel color change mechanism for breast cancer biomarker detection: naphthoquinones as specific ligands of human arylamine N-acetyltransferase 1
PLoS ONE
8
e70600
2013
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Kleinpenning, F.; Eising, S.; Berkenbosch, T.; Garzero, V.; Schaart, J.M.; Bonger, K.M.
Subcellular protein labeling by a spatially restricted arylamine N-acetyltransferase
ACS Chem. Biol.
13
1932-1937
2018
Homo sapiens (P18440)
Manually annotated by BRENDA team
Doll, M.A.; Salazar-Gonzalez, R.A.; Bodduluri, S.; Hein, D.W.
Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes
Acta Pharm. Sin. B
7
517-522
2017
Homo sapiens (P11245), Homo sapiens
Manually annotated by BRENDA team
Turijan-Espinoza, E.; Salazar-Gonzalez, R.A.; Uresti-Rivera, E.E.; Hernandez-Hernandez, G.E.; Ortega-Juarez, M.; Milan, R.; Portales-Perez, D.
A pilot study of the modulation of sirtuins on arylamine N-acetyltransferase 1 and 2 enzymatic activity
Acta Pharm. Sin. B
8
188-199
2018
Homo sapiens (P11245), Homo sapiens (P18440)
Manually annotated by BRENDA team
Salazar-Gonzalez, R.A.; Turijan-Espinoza, E.; Hein, D.W.; Nino-Moreno, P.C.; Romano-Moreno, S.; Milan-Segovia, R.C.; Portales-Perez, D.P.
Arylamine N-acetyltransferase 1 in situ N-acetylation on CD3+ peripheral blood mononuclear cells correlate with NATb mRNA and NAT1 haplotype
Arch. Toxicol.
92
661-668
2018
Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Witham, K.L.; Minchin, R.F.; Butcher, N.J.
Role for human arylamine N-acetyltransferase 1 in the methionine salvage pathway
Biochem. Pharmacol.
125
93-100
2017
Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Minchin, R.F.; Rosengren, K.J.; Burow, R.; Butcher, N.J.
Allosteric regulation of arylamine N-acetyltransferase 1 by adenosine triphosphate
Biochem. Pharmacol.
158
153-160
2018
Homo sapiens (P18440)
Manually annotated by BRENDA team
Wang, T.; Marei, H.E.
Landscape of NAT2 polymorphisms among breast cancer
Biomed. Pharmacother.
77
191-196
2016
Homo sapiens
Manually annotated by BRENDA team
Li, P.; Butcher, N.J.; Minchin, R.F.
Effect arylamine N-acetyltransferase 1 on morphology, adhesion, migration, and invasion of MDA-MB-231 cells role of matrix metalloproteinases and integrin alphaV
Cell Adh. Migr.
14
1-11
2020
Homo sapiens
Manually annotated by BRENDA team
Wang, L.; Minchin, R.F.; Essebier, P.J.; Butcher, N.J.
Loss of human arylamine N-acetyltransferase I regulates mitochondrial function by inhibition of the pyruvate dehydrogenase complex
Int. J. Biochem. Cell Biol.
110
84-90
2019
Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Cloete, R.; Akurugu, W.A.; Werely, C.J.; van Helden, P.D.; Christoffels, A.
Structural and functional effects of nucleotide variation on the human TB drug metabolizing enzyme arylamine N-acetyltransferase 1
J. Mol. Graph. Model.
75
330-339
2017
Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Stepp, M.W.; Doll, M.A.; Carlisle, S.M.; States, J.C.; Hein, D.W.
Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231
Mol. Carcinog.
57
549-558
2018
Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Xu, X.; Mathieu, C.; Berthelet, J.; Duval, R.; Bui, L.C.; Busi, F.; Dupret, J.M.; Rodrigues-Lima, F.
Human arylamine N-acetyltransferase 1 is inhibited by the dithiocarbamate pesticide thiram
Mol. Pharmacol.
92
358-365
2017
Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Li, P.; Butcher, N.J.; Minchin, R.F.
Arylamine N-acetyltransferase 1 regulates expression of matrix metalloproteinase 9 in breast cancer cells role of hypoxia-inducible factor 1-alpha
Mol. Pharmacol.
96
573-579
2019
Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Gao, S.; Tan, H.; Lang, L.; Bai, J.; Ji, Y.
The effect of alpha-solanine on the activity, gene expression, and kinetics of arylamine N-acetyltransferase in HepG2 cells
Oncol. Rep.
39
2427-2435
2018
Homo sapiens (P11245)
Manually annotated by BRENDA team
Wang, L.; Minchin, R.F.; Butcher, N.J.
Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation Role in the regulation of p53 stability
PLoS ONE
13
e0193560
2018
Homo sapiens (P18440), Homo sapiens
Manually annotated by BRENDA team
Hein, D.W.; Zhang, X.; Doll, M.A.
Role of N-acetyltransferase 2 acetylation polymorphism in 4, 4-methylene bis (2-chloroaniline) biotransformation
Toxicol. Lett.
283
100-105
2018
Homo sapiens (P11245), Homo sapiens
Manually annotated by BRENDA team